Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. More Details
Very undervalued with excellent balance sheet.
Share Price & News
How has Antares Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MJC is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: MJC's weekly volatility (6%) has been stable over the past year.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: MJC exceeded the German Medical Equipment industry which returned 41.5% over the past year.
Return vs Market: MJC matched the German Market which returned 42.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Antares Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Antares Pharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MJC (€3.4) is trading below our estimate of fair value (€12.59)
Significantly Below Fair Value: MJC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MJC is good value based on its PE Ratio (11.9x) compared to the DE Medical Equipment industry average (46.3x).
PE vs Market: MJC is good value based on its PE Ratio (11.9x) compared to the German market (28.2x).
Price to Earnings Growth Ratio
PEG Ratio: MJC is good value based on its PEG Ratio (1x)
Price to Book Ratio
PB vs Industry: MJC is good value based on its PB Ratio (5.7x) compared to the DE Medical Equipment industry average (7.9x).
How is Antares Pharma forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MJC's forecast earnings growth (12.3% per year) is above the savings rate (0.07%).
Earnings vs Market: MJC's earnings (12.3% per year) are forecast to grow slower than the German market (20.9% per year).
High Growth Earnings: MJC's earnings are forecast to grow, but not significantly.
Revenue vs Market: MJC's revenue (14.6% per year) is forecast to grow faster than the German market (5.4% per year).
High Growth Revenue: MJC's revenue (14.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MJC's Return on Equity is forecast to be high in 3 years time
How has Antares Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MJC has a high level of non-cash earnings.
Growing Profit Margin: MJC became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: MJC has become profitable over the past 5 years, growing earnings by 59.6% per year.
Accelerating Growth: MJC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MJC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (44.3%).
Return on Equity
High ROE: MJC's Return on Equity (47.2%) is considered outstanding.
How is Antares Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: MJC's short term assets ($126.6M) exceed its short term liabilities ($63.2M).
Long Term Liabilities: MJC's short term assets ($126.6M) exceed its long term liabilities ($30.2M).
Debt to Equity History and Analysis
Debt Level: MJC's debt to equity ratio (34.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if MJC's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: MJC's debt is well covered by operating cash flow (52.1%).
Interest Coverage: MJC's interest payments on its debt are well covered by EBIT (3.6x coverage).
What is Antares Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MJC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MJC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MJC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MJC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MJC's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bob Apple (54 yo)
Mr. Robert F. Apple, also known as Bob, has been the Chief Executive Officer and President of Antares Pharma Inc. since January 25, 2016. Mr. Apple served as Chief Operating Officer of Antares Pharma Inc. ...
CEO Compensation Analysis
Compensation vs Market: Bob's total compensation ($USD3.51M) is above average for companies of similar size in the German market ($USD1.15M).
Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.
Experienced Management: MJC's management team is considered experienced (4.5 years average tenure).
Experienced Board: MJC's board of directors are considered experienced (7.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Antares Pharma, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Antares Pharma, Inc.
- Ticker: MJC
- Exchange: DB
- Founded: 1978
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$679.371m
- Listing Market Cap: US$567.411m
- Shares outstanding: 168.16m
- Website: https://www.antarespharma.com
Number of Employees
- Antares Pharma, Inc.
- 100 Princeton South
- Suite 300
- New Jersey
- United States
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therape...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/14 18:31|
|End of Day Share Price||2021/04/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.